Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 52 от 222

Recruiting Phase 4

Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease

Moderate to Severe COPD

The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.

Начало: 19.12.2025 Край: 30.12.2027 Възраст: от 18 г.

India AstraZeneca NCT06531798

Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Myasthenia Gravis MG gMG Generalized Myasthenia Gravis +2

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

Начало: 19.12.2025 Край: 07.03.2028 Възраст: от 18 г.

Belgium, Poland, Spain +1 argenx NCT07294170

Recruiting Phase 2

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Malignant Neoplasm

Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.

Начало: 19.12.2025 Край: 14.01.2033 Възраст: от 18 г.

China, Finland, Netherlands +4 Merck Sharp & Dohme LLC NCT07252739

Recruiting Phase 4

Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients

Acute Ischemic Stroke Patients

The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.

Начало: 19.12.2025 Край: 31.12.2028 Възраст: от 70 г.

China Southwest Hospital, China NCT07294209

Recruiting Phase 2

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA)

This study aims to find the correct dose of ARGX-119 for children with SMA. The study will also look at how safe the study drug is, how well it works, how it moves through the body, and how the immune system responds to it. The study consists of a double-blinded treatment period (DBTP) where participants will either receive ARGX-119 IV or placebo IV, in addition to disease-modifying therapy (DMT) for 24 weeks. Participants who complete the DBTP will enter the open-label active-treatment extension period (ATEP) during which all participants will receive ARGX-119 IV up to 100 weeks (approximately 2 years).

Начало: 19.12.2025 Край: 28.05.2029 Възраст: 5–17 г.

United States argenx NCT07287982

Recruiting Phase 1

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

Graves Disease

The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Начало: 19.12.2025 Край: 24.07.2028 Възраст: 18–55 г.

United States Merida Biosciences NCT07305818

Recruiting Phase 4

Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis

Osteoarthritis Hand Osteoarthritis Wrist

The purpose of this research is to compare low-dose radiotherapy to corticosteroid injection for treatment of hand/wrist osteoarthritis.

Начало: 19.12.2025 Край: 01.10.2027 Възраст: от 50 г.

United States Mayo Clinic NCT07217405

Recruiting Phase 3

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).

Начало: 19.12.2025 Край: 20.07.2029 Възраст: от 18 г. Treatment

Australia, Belgium, Brazil +12 Janssen Research & Development, LLC NCT07225946

Recruiting Phase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity Obstructive Sleep Apnea

This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

Начало: 19.12.2025 Край: 13.09.2028 Възраст: 18–99 г. Treatment

Australia, Brazil, Canada +8 Amgen NCT07225686

Recruiting Phase 2

Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

Castleman's Disease (CD) Idiopathic Multicentric Castleman's Disease

The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.

Начало: 18.12.2025 Край: 31.12.2028 Възраст: 18–80 г.

United States University of Pennsylvania NCT07085039

Recruiting Phase 3

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Hemophilia

This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to \

Начало: 18.12.2025 Край: 30.12.2031 Възраст: 1–11 г.

Belgium, Brazil, Canada +7 Sanofi NCT07285460

Recruiting Phase 2/3

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to learn: 1) If the study ART works as well as a standard ART to treat HIV-1, and 2) About the safety of the study ART and if people tolerate it compared to a standard ART.

Начало: 18.12.2025 Край: 03.04.2030 Възраст: от 18 г.

Argentina, Canada, France +5 Merck Sharp & Dohme LLC NCT07266831

Recruiting

A Feasibility Study Implant of the WiSE® CRT System With an Intracardiac Pacemaker to Achieve Totally Leadless CRT

Heart Failure

Assess the safety and efficacy of the co-implantation of the WiSE CRT System with an intracardiac pacemaker to provide totally leadless CRT.

Начало: 18.12.2025 Край: 01.04.2027 Възраст: от 22 г. Treatment

Australia EBR Systems, Inc. NCT06561932

Recruiting

Just-in-Time Training for Youth Mentors

Mental Health Issue Depression Anxiety

This study will evaluate the usability, feasibility, and acceptability of a novel multi-level Just-In-Time Training (JITT) implementation strategy (JITT-EBP) that aims to equip mentors and mentor supervisors to implement evidence-based practices (EBPs) with fidelity using methods that are sustainable in rural communities. JITT-EBP integrates (a) self-directed, on-demand, online training modules for mentors and mentor supervisors, (b) synchronous evidence-based supervision strategies, and (c) an apprenticeship delivery model in which EBPs are co-led by an experienced mentor and a novice mentor, providing opportunity for in-the-moment training and support. The study will conduct a pilot hybrid type 2 effectiveness-implementation trial to evaluate the use of JITT-EBP compared to usual training for implementing mentor-delivered Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST), an evidence-based depression prevention program. 96 adolescents (age 12-17) and their parents, 8-18 mentors (depending on amount of turnover), and 4 mentor supervisors will be enrolled in the trial.

Начало: 18.12.2025 Край: 31.05.2028 Възраст: от 12 г.

United States University of Minnesota NCT07129070

Recruiting

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

Hidradenitis Suppurativa

The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on secukinumab, healthcare resource utilization and the economic impact of HS in Italy.

Начало: 17.12.2025 Край: 30.09.2028 Възраст: 18–100 г.

Italy Novartis Pharmaceuticals NCT07543419

Recruiting

RESCUE: Discontinuation of GLP-1

Obesity

This study is designed to compare weight loss outcomes and safety of ESG versus lifestyle modification in patients with obesity who discontinued GLP-1 therapy due to intolerance or suboptimal weight loss.

Начало: 17.12.2025 Край: 01.06.2026 Възраст: от 18 г.

United States Boston Scientific Corporation NCT07190794

Recruiting

Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor

Cystic Fibrosis (CF) Mucoviscidosis

Cystic fibrosis is a genetic disorder affecting the entire body and associated with respiratory exacerbations, impaired quality of life and reduced life expectancy. The therapeutic management of cystic fibrosis has been profoundly changed by the recent arrival of a combination of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Elexacaftor-Tezacaftor-Ivacaftor (ETI), which improve quality of life, respiratory function and reducing the number of exacerbations. The impact of these treatments on exercise adaptation has not been clearly identified. The main objective is to estimate the prevalence of ventilatory reserve amputation during submaximal exercise testing assessed by the 6-minute walk test (6MWT) in patients with cystic fibrosis treated with ETIs.

Начало: 17.12.2025 Край: 04.04.2027 Възраст: от 18 г.

France University Hospital, Lille NCT07314229

Recruiting

A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry

Hemolytic Disease of the Fetus and Newborn

The purpose of this non-interventional study is to prospectively evaluate the risk of anemia (decreased red blood cells) in fetuses (baby before birth) and neonates (baby just after birth) of pregnant participants who are at risk for hemolytic disease of the fetus and newborn (HDFN) and receiving standard of care (SoC). HDFN is a blood disease that occurs in babies before birth or just after birth when the blood types of the pregnant individual and babies are incompatible, thus resulting in fast breakdown of red blood cells (RBCs) of the fetus/baby.

Начало: 17.12.2025 Край: 30.09.2030 Възраст: от 18 г.

Australia, Germany, Italy +2 Janssen Research & Development, LLC NCT07194070

Recruiting Phase 1/2

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

Melanoma (Skin) Non Small Cell Lung Cancer Breast Cancer

This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The study consists of 2 phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2). The primary objectives of Phase 1 are to characterize the overall safety and tolerability profile of increasing doses of HMBD-501 in patients with advanced-stage solid tumors and identify the recommended Phase 2 dose (RP2D) of ENV-501. During Phase 1, successive cohorts of patients will receive escalating doses of HMBD-501. The results of the dose escalation will determine the RP2D and dosing schedule of HMBD-501 to be administered in the Phase 2 part of the study. The primary objective of Phase 2 is to evaluate the preliminary clinical efficacy of HMBD-501 in dose expansion cohorts.

Начало: 17.12.2025 Край: 01.07.2027 Възраст: от 18 г. Treatment

Australia, United States Hummingbird Bioscience NCT06956690

Recruiting Phase 1/2

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Advanced Solid Tumors

The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes OTP-01 by measuring drug levels in the blood. The main questions this study aims to answer are: * What is the recommended dose of OTP-01 for adults with solid tumors? * Is OTP-01 safe and tolerable? * Does OTP-01 reduce tumor growth? Participants will: * Receive OTP-01 through an infusion into a vein. Doses will be spaced out and never more than once a week. * Have blood tests to evaluate safety and drug levels of OTP-01. These will be done often at first and then less frequently as treatment continues. * Have radiographic scans of their tumor at baseline and during the study at regular intervals. * Have the choice to have an optional tumor biopsy before and after treatment to help researchers understand how OTP-01 affects cancer and the immune system. These biopsies are voluntary and will not affect participation in the study.

Начало: 17.12.2025 Край: 01.12.2028 Възраст: от 18 г. Other

Australia, New Zealand, United States Ottimo Pharma Limited NCT07266428

1 … 50 51 52 53 54 … 222